Clinical observation of FOLFIRI as second-line chemotherapy for advanced duodenal cancer
PAN Jun
QIN Shukui
YANG Ningrong
HAO Liping
ZHAO Xiaoyue
WANG Lin
Abstract：Objective To evaluate the efficacy and safety of FOLFIRI as second-line chemotherapy for advanced duodenal cancer.Methods Patients with advanced duodenal cancer who have failed to first-line therapy from June 2008 to January 2016 were analyzed retrospectively.Nine patients received FOLFIRI regiments as second-line chemotherapy.The efficacy and safety were evaluated by RECIST 1.1 and NCI-CTC 4.0 criteria.Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier method.Results All patients were available for evaluating toxicity and effectiveness.The total treatment cycle was 41, and the median treatment cycle was 4(3-8 cycles).The response rate was 11.1% and disease control rate was 66.7%, including 1 case of PR, 5 cases of SD and 3 cases of PD.The median OS was 19.3 months and the median PFS was 6.5 months.The major treatment-related side effects including leucopenia, neutropenia, anemia, fatigue, nausea and etc, were mainly in grade 1-grade 2.Conclusion FOLFIRI is effective and tolerable in advanced duodenal cancer as second-line chemotherapy.
Keywords：Advanced duodenal cancerFOLFIRI regimenSecond-line chemotherapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 446-449 )